Pfizer's Crizotinib, also trading as Xalkori, has been announced as being beneficial to 5 in 100 lung cancer patients.
Crizotinib caused tumours to shrink or stabilise in 90% of 82 patients carrying the ALK fusion gene. Tumours shrank at least 30% in 57% of people treated.
Most had adenocarcinoma, and had never smoked or were former smokers. They had undergone treatment with an average of three other drugs prior to receiving crizotinib, and only 10% were expected to respond to standard therapy.
They were given 250 mg Crizotinib twice daily for a median duration of six months. Approximately 50% of these patients suffered at least one side effect, such as nausea, vomiting, or diarrhea.
Some responses to crizotinib have lasted up to 15 month.
Read more on this story Here
Posts
No comments:
Post a Comment